CL2016001448A1 - Forma cristalina de anhidrato de 7-[3a,5a-dihidroxi-2-(3a-hidroxi-5-(3-(2,5-dicloro)tienil)-1e-pentenil)ciclopentil]-5z-heptenamida (forma b), composición farmacéutica que la comprende, método de preparación, útil en el tratamiento de la hipertensión ocular y el glaucoma en un sujeto que lo necesita - Google Patents
Forma cristalina de anhidrato de 7-[3a,5a-dihidroxi-2-(3a-hidroxi-5-(3-(2,5-dicloro)tienil)-1e-pentenil)ciclopentil]-5z-heptenamida (forma b), composición farmacéutica que la comprende, método de preparación, útil en el tratamiento de la hipertensión ocular y el glaucoma en un sujeto que lo necesitaInfo
- Publication number
- CL2016001448A1 CL2016001448A1 CL2016001448A CL2016001448A CL2016001448A1 CL 2016001448 A1 CL2016001448 A1 CL 2016001448A1 CL 2016001448 A CL2016001448 A CL 2016001448A CL 2016001448 A CL2016001448 A CL 2016001448A CL 2016001448 A1 CL2016001448 A1 CL 2016001448A1
- Authority
- CL
- Chile
- Prior art keywords
- heptenamide
- anhydrate
- glaucoma
- pentenyl
- dihydroxy
- Prior art date
Links
- 208000010412 Glaucoma Diseases 0.000 title abstract 2
- 206010030043 Ocular hypertension Diseases 0.000 title abstract 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 125000001544 thienyl group Chemical group 0.000 title abstract 2
- 238000002360 preparation method Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/559—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing hetero atoms other than oxygen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/28—Halogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361915575P | 2013-12-13 | 2013-12-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2016001448A1 true CL2016001448A1 (es) | 2017-03-03 |
Family
ID=52282957
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2016001448A CL2016001448A1 (es) | 2013-12-13 | 2016-06-10 | Forma cristalina de anhidrato de 7-[3a,5a-dihidroxi-2-(3a-hidroxi-5-(3-(2,5-dicloro)tienil)-1e-pentenil)ciclopentil]-5z-heptenamida (forma b), composición farmacéutica que la comprende, método de preparación, útil en el tratamiento de la hipertensión ocular y el glaucoma en un sujeto que lo necesita |
| CL2019000471A CL2019000471A1 (es) | 2013-12-13 | 2019-02-22 | Formas sólidas de un compuesto de dihidroxi ciclopentilo disustituido con alfa, omega y métodos para su preparación y uso. (divisional solicitud 201601448) |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2019000471A CL2019000471A1 (es) | 2013-12-13 | 2019-02-22 | Formas sólidas de un compuesto de dihidroxi ciclopentilo disustituido con alfa, omega y métodos para su preparación y uso. (divisional solicitud 201601448) |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US9353079B2 (enExample) |
| EP (1) | EP3080096A1 (enExample) |
| JP (2) | JP2016539994A (enExample) |
| KR (1) | KR20160097310A (enExample) |
| CN (1) | CN105814033B (enExample) |
| AU (1) | AU2014361794B2 (enExample) |
| BR (1) | BR112016013594A8 (enExample) |
| CA (1) | CA2933556A1 (enExample) |
| CL (2) | CL2016001448A1 (enExample) |
| IL (2) | IL245917B (enExample) |
| MX (1) | MX2016007717A (enExample) |
| RU (1) | RU2730520C2 (enExample) |
| SA (1) | SA516371307B1 (enExample) |
| SG (2) | SG11201604787SA (enExample) |
| UA (1) | UA121108C2 (enExample) |
| WO (1) | WO2015089475A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12478503B2 (en) | 2009-05-18 | 2025-11-25 | Glaukos Corporation | Implants with controlled drug delivery features and methods of using same |
| US10206813B2 (en) | 2009-05-18 | 2019-02-19 | Dose Medical Corporation | Implants with controlled drug delivery features and methods of using same |
| US10765629B2 (en) * | 2017-07-25 | 2020-09-08 | Allergan, Inc. | Solid complex, preparations and uses thereof |
| US20230338194A1 (en) * | 2020-01-29 | 2023-10-26 | Kci Licensing, Inc. | Mutliple fluid pathway connector with foam supports |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO143741C (no) * | 1972-07-13 | 1981-04-08 | Pfizer | Analogifremgangsmaate for fremstilling av fysiologisk aktive prostaglandinforbindelser av e- og f-serien |
| US5296504A (en) * | 1988-09-06 | 1994-03-22 | Kabi Pharmacia | Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension |
| US6602900B2 (en) | 1992-09-21 | 2003-08-05 | Allergan, Inc. | Cyclopentane heptan(ENE)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents |
| US5834498A (en) * | 1992-09-21 | 1998-11-10 | Allergan | Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents |
| US6124344A (en) * | 1993-12-28 | 2000-09-26 | Allergan Sales, Inc. | Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents |
| DE69613693T2 (de) * | 1995-05-18 | 2002-05-16 | Allergan Sales, Inc. | 2-heteroarylalkenylderivate der cyclopentano-heptan(heptaen)säure als therapeutisches mittel zur behandlung des erhöhten augeninnendruckes |
-
2014
- 2014-12-12 MX MX2016007717A patent/MX2016007717A/es unknown
- 2014-12-12 SG SG11201604787SA patent/SG11201604787SA/en unknown
- 2014-12-12 AU AU2014361794A patent/AU2014361794B2/en not_active Ceased
- 2014-12-12 EP EP14824284.5A patent/EP3080096A1/en not_active Withdrawn
- 2014-12-12 CA CA2933556A patent/CA2933556A1/en not_active Abandoned
- 2014-12-12 JP JP2016538513A patent/JP2016539994A/ja active Pending
- 2014-12-12 KR KR1020167018489A patent/KR20160097310A/ko not_active Ceased
- 2014-12-12 CN CN201480067663.3A patent/CN105814033B/zh not_active Expired - Fee Related
- 2014-12-12 SG SG10201709702UA patent/SG10201709702UA/en unknown
- 2014-12-12 RU RU2016123446A patent/RU2730520C2/ru active
- 2014-12-12 UA UAA201606260A patent/UA121108C2/uk unknown
- 2014-12-12 BR BR112016013594A patent/BR112016013594A8/pt not_active IP Right Cessation
- 2014-12-12 WO PCT/US2014/070156 patent/WO2015089475A1/en not_active Ceased
- 2014-12-12 US US14/569,210 patent/US9353079B2/en active Active
-
2016
- 2016-05-05 US US15/147,700 patent/US20170087163A1/en not_active Abandoned
- 2016-05-30 IL IL245917A patent/IL245917B/en active IP Right Grant
- 2016-06-10 CL CL2016001448A patent/CL2016001448A1/es unknown
- 2016-06-13 SA SA516371307A patent/SA516371307B1/ar unknown
-
2019
- 2019-02-22 CL CL2019000471A patent/CL2019000471A1/es unknown
- 2019-12-23 JP JP2019231685A patent/JP2020073513A/ja active Pending
-
2021
- 2021-06-08 IL IL283810A patent/IL283810A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RU2730520C2 (ru) | 2020-08-24 |
| US9353079B2 (en) | 2016-05-31 |
| CN105814033A (zh) | 2016-07-27 |
| UA121108C2 (uk) | 2020-04-10 |
| CA2933556A1 (en) | 2015-06-18 |
| AU2014361794A1 (en) | 2016-06-16 |
| AU2014361794B2 (en) | 2019-04-04 |
| CN105814033B (zh) | 2019-10-25 |
| IL245917A0 (en) | 2016-08-02 |
| EP3080096A1 (en) | 2016-10-19 |
| SG11201604787SA (en) | 2016-07-28 |
| US20150166504A1 (en) | 2015-06-18 |
| IL283810A (en) | 2021-07-29 |
| BR112016013594A8 (pt) | 2020-05-19 |
| JP2016539994A (ja) | 2016-12-22 |
| US20170087163A1 (en) | 2017-03-30 |
| SA516371307B1 (ar) | 2018-10-04 |
| KR20160097310A (ko) | 2016-08-17 |
| BR112016013594A2 (enExample) | 2017-08-08 |
| IL245917B (en) | 2021-06-30 |
| SG10201709702UA (en) | 2018-01-30 |
| WO2015089475A1 (en) | 2015-06-18 |
| MX2016007717A (es) | 2016-09-09 |
| CL2019000471A1 (es) | 2019-07-12 |
| JP2020073513A (ja) | 2020-05-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1123953T1 (el) | Καθυστερημενης απελευθερωσης συνθεσεις λινακλοτιδης | |
| MX2018006637A (es) | Antagonistas policiclicos del receptor 7/8 tipo toll (tlr7/8) y uso de los mismos en el tratamiento de trastornos inmunitarios. | |
| BR112015020389A2 (pt) | compostos carbazol úteis como inibidores de bromodomínio | |
| NI201700135A (es) | Derivados de ciclohexano sustituido con amido | |
| EA201890942A1 (ru) | Мультивалентные вакцины с синтетическими наноносителями | |
| EA201692301A1 (ru) | Производные бороновой кислоты и их терапевтическое применение | |
| CR20170060A (es) | Anticuerpos anti tigit | |
| UY34474A (es) | Composiciones, forma de dosificación y métodos para tratar el virus de la hepatitis C. | |
| EA201492040A1 (ru) | Бициклически замещённые урацилы и их применение | |
| BR112015029686A2 (pt) | composições para o tratamento de superfícies compreendendo corantes fotocrômicos | |
| MX2021005052A (es) | Oxiesteroles y métodos de uso de los mismos. | |
| MX381497B (es) | Composiciones vacuna. | |
| EA201691044A1 (ru) | Новый октагидро-циклобута[1,2-c;3,4-c']дипиррол-2-ил | |
| MX376122B (es) | Composiciones de plinabulina. | |
| EA201591618A1 (ru) | Замещенные имидазопиридазины | |
| UA113962C2 (xx) | Фармацевтична композиція, яка містить апоморфін як активний інгредієнт | |
| CR20170008A (es) | Compuestos de [1,2,4] triazol e imidazol sustituidos | |
| UA115357C2 (uk) | Похідні піридин-4-ілу | |
| MX2015017863A (es) | Moduladores de receptor de hormona de crecimiento. | |
| CU20160003A7 (es) | Pirazololpiridinaminas sustituidas | |
| PH12015502747A1 (en) | Novel compounds for the treatment of cancer | |
| CA2922375C (en) | Alpha-tea salt forms: compositions and uses for treating disease | |
| CL2015001881A1 (es) | Compuesto 4-hidroxi-2-metil-5-(propan-2-iliden)ciclohexil-3-en-1-carbaldehido; uso del compuesto para el tratamiento de la enfermedad de alzheimer; composición farmacéutica; método para preparar la composición. | |
| EA201591449A1 (ru) | Способы получения противораковых композиций | |
| ECSP17071769A (es) | Derivados de aminohidrotiazina fusionados con tetrahidrofurano los cuales son útiles en el tratamiento de la enfermedad de alzheimer |